Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
|
|
- Spencer Johnson
- 5 years ago
- Views:
Transcription
1 Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD Superbugs & Superdrugs USA, November 14-15, 2016, Iselin, NJ
2 Overview of presentation Co-evolution of β lactams, β lactamases and their inhibitors Multidrug resistant Acinetobacter baumannii: an unmet medical need ETX2514 In vitro characterization In vivo efficacy 2
3 β-lactamases are characterized into four molecular classes Class B are metalloenzymes that require zinc at the active site Class A, C, and D have a serine at the active site and require water in the active site for β-lactam hydrolysis Drawz & Bonomo, (2010) Clin. Microbiol. Rev. 23:
4 β-lactamases evolve after use of β-lactam antibiotics Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s 1 st Gen Cephalosporins Cefalothin Cephalexin Cefazolin 4
5 β-lactamases evolve after use of β-lactam antibiotics: TEM-1, SHV-1 Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s 1 st Gen Cephalosporins 2 nd Gen Cephalosporins Cephamycins Cefaclor Cefotetan β-lactam drugs Cefoxitin 5
6 β-lactamases evolve after use of β-lactam antibiotics: TEM-1, SHV-1 AmpC overexpression Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s 1 st Gen Cephalosporins 2 nd Gen Cephalosporins Cephamycins 3 rd Gen Cephalosporins Monobactam 1 st Gen BL/BLI combinations Cefotaxime Ceftazidime β-lactam drugs Aztreonam Amoxicillin/Clavulanate, Ampicillin/Sulbactam 6
7 β-lactamases evolve after use of β-lactam antibiotics: TEM-1, SHV-1 AmpC overexpression ESBL TEM, SHV ESBL CTX-M ESBL OXA Class A Class B Class C Class D 1960s 1970s Plasmid AmpC 1980s 1990s 2000s 2010s 2020s 1 st Gen Cephalosporins 2 nd Gen Cephalosporins Cephamycins 3 rd Gen Cephalosporins Monobactam 1 st Gen BL/BLI combinations Carbapenems 2 nd Gen BL/BLI Imipenem Meropenem β-lactam drugs Piperacillin/tazobactam 7
8 β-lactamases evolve after use of β-lactam antibiotics: TEM-1, SHV-1 AmpC overexpression ESBL TEM, SHV ESBL CTX-M ESBL OXA Plasmid AmpC KPC carbapenemase VIM OXA carbapenemase NDM Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s 1 st Gen Cephalosporins β-lactam drugs 2 nd Gen Cephalosporins Cephamycins 3 rd Gen Cephalosporins Monobactam 1 st Gen BL/BLI combinations Carbapenems 2 nd Gen BL/BLI No new β-lactams for Gramnegatives Therapy limited to colistin or tigecycline 8
9 Older β-lactamase inhibitors only work against a few classes of β-lactamases TEM-1, SHV-1 AmpC overexpression ESBL TEM, SHV ESBL CTX-M ESBL OXA Plasmid AmpC KPC carbapenemase VIM OXA carbapenemase NDM Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s Inhibited by Clavulanic Acid and Sulbactam Amoxicillin-clavulanate Ticarcillin-clavulanate Ampicillin-sulbactam clavulanic acid 9
10 Older β-lactamase inhibitors only work against a few classes of β-lactamases TEM-1, SHV-1 AmpC overexpression ESBL TEM, SHV ESBL CTX-M ESBL OXA Plasmid AmpC KPC carbapenemase VIM OXA carbapenemase NDM Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s Inhibited by Tazobactam Piperacillin-tazobactam Ceftolozane-tazobactam (Zerbaxa) tazobactam 10
11 Avibactam and other DABCO*s have broader spectra of inhibition than older β-lactamase inhibitors TEM-1, SHV-1 AmpC overexpression ESBL TEM, SHV ESBL CTX-M ESBL OXA Plasmid AmpC KPC carbapenemase VIM OXA carbapenemase NDM Class A Class B Class C Class D 1960s 1970s 1980s 1990s 2000s 2010s 2020s Inhibited by Avibactam Ceftazidime-avibactam (AvyCaz) Imipenem-relebactam (Ph III) Zidebactam, RG6080 (Ph I) Aztreonam-avibactam (Ph I) MBL + Enterobacteriaceae (Class B) (ATM is not degraded by MBLs; AVI inhibits serine BLs) *di-aza-bicyclo-octanone 11
12 Very limited coverage of Class D -lactamases by avibactam Class A Class B Class C Class D Inhibited by Avibactam ESBL TEM, SHV TEM-1, SHV-1 ESBL CTX-M AmpC overexpression ESBL OXA Plasmid AmpC OXA carbapenemase KPC carbapenemase VIM Addressed by ATM-AVI in Enterobacteriaceae NDM 1960s 1970s 1980s 1990s 2000s 2010s 2020s Gaps in Coverage 12
13 Multi-drug resistant Acinetobacter baumannii Gram-negative bacteria that causes infections in critically ill patients, with mortality rates as high as 43% 1 CDC Unmet Need Threat Level: Serious 2 63% of A. baumannii isolates are considered multidrug resistant, meaning at least three different classes of antibiotics no longer cure A. baumannii infections including carbapenems, often considered antibiotics of last resort Resistance to carbapenems in A. baumannii is associated with increasing prevalence of Class D -lactamases 3,4 A. baumannii 1. Am. J. Respir. Crit. Care Med ; Int. J. Antimicrob. Agents CDC Antibiotic Resistant Threats in the US. pg M.M. Ehlers, et. al InTech, DOI: / Potron, et al Int. J. Antimicrob. Agents 45:568 13
14 Complexity of β-lactamase content in A. baumannii Whole-genome sequencing of 84 recent MDR A. baumannii strains provides insight into what is required for a successful next generation BL/BLI therapy Class N % Most prevalent variant(s) A TEM-1 (41/45) B IMP-1 Extended spectrum C* ADC-30 (18/84) ADC-73 (18/84) Multiple (70/84 encode two or more, (46/70 D were OXA-23+OXA-51- like) *all strains contain chromosomal adc gene Inhibition of Classes A, C and D Required for Robust BLI Activity in A. baumannii 14
15 The ultimate medicinal chemistry challenge How to selectively inhibit hundreds of bacterial enzymes? How to find the right balance between reactivity and hydrolytic stability? How to prepare synthetically challenging, diverse analogs to verify structural hypotheses? A deep understanding of avibactam s biology informed design of the next generation BLI Crystal structures provided insights to avibactam s unique interactions with -lactamases Avibactam-bound structures of CTX-M-15 at 1.1Å, From Lahiri et al (2013) AAC 57:
16 Discovery of ETX2514, a novel broad-spectrum serine BLI Using a combination of innovative chemistry and structure-based design avibactam di-aza-bicyclo-octenone Active site overlays of avibactam- (in grey, PDB: 4WM9) and an ETX2514 analog- (in green) bound OXA-24 structures. The water molecules are depicted as spheres. The hydrogen bonding network around the ETX2514 analog is shown in dashed lines. 16
17 ETX2514 exhibits excellent β-lactamase inhibition across classes A, C and D IC 50 after 5 min incubation (in µm) Class A Class C Class D Compound Name9.2 E. cloacae TEM-1 K. pneumoniae CTX-M-15 E. cloacae KPC-2 E. cloacae P99 P. aeruginosa AmpC P. aeruginosa OXA-10 A. baumannii OXA-24/40 K. pneumoniae OXA-48 Avibactam ETX Fold increase in potency 9X 6X 44X 154X 44X 92X 80X 119X 17
18 Exceptional enzymatic spectrum translates into excellent activity across an isogenic panel of P. aeruginosa strains IC 50 (in µm) Compound Name E. cloacae TEM-1 Class A Class C Class D K. pneumoniae E. cloacae E. cloacae P. aeruginosa P. aeruginosa A. baumannii CTX-M-15 KPC-2 P99 AmpC OXA-10 OXA-24/40 K. pneumoniae OXA-48 Avibactam ETX MIC (in mg/l) Compound Name Piperacillin alone Piperacillin +Avibactam Piperacillin +ETX2514 Vector alone P. aeruginosa isogenic strains bearing corresponding -lactamases TEM-1 CTX-M-15 KPC-2 P99 AmpC OXA-10 OXA-24/40 OXA-48 4 > No BLI BLI added at 4 mg/ml 18
19 Aztreonam Inhibition of PBP2 by ETX2514 results in intrinsic antibacterial activity vs. Enterbacteriaceae Pathogen ETX2514 k inact /K i in M -1 s -1 PBP1a PBP2 PBP3 A. baumannii 180 Control 1,800 3 P. aeruginosa E. coli ,000 2 Mecillinam Morphology of antibiotic-treated E. coli Control Control Aztreonam Aztreonam (PBP3-selective inhibitor) Mecillinam (PBP2-selective Mecillinam inhibitor) ETX2514 ETX2514 Linneas Bioscience
20 ETX2514 restores β-lactam activity vs. multiple gram-negative pathogens Excellent activity vs E. coli & K. pneumoniae with all β-lactams tested Restores imipenem to MIC 90 of 2 mg/l vs P. aeruginosa Restores sulbactam to MIC 90 of 4 mg/l vs A. baumannii MIC 90 across recent clinical isolates (+/- ETX2514 at 4 mg/l) Compound Imipenem Meropenem Aztreonam Ceftazidime Sulbactam E. coli n = 202 K. pneumoniae n = 198 P. aeruginosa n = 202 A. baumannii n = 195 alone >64 + ETX alone >64 + ETX alone >64 + ETX >64 alone 16 >64 >64 >64 + ETX alone 64* >64 > ETX * 0.12 >64 4 ETX2514 alone 1 8 >64 >64 *n = 21 strains n = 20 strains 20
21 Intrinsic activity of sulbactam vs. A. baumannii Attributed to inhibition of PBP3 untreated + sulbactam Frequency of resistance is low: 2-4x10-9 at 4X MIC Resistance maps to residues near active site of PBP3 Resistant mutants are attenuated in fitness Penwell et al.(2015) AAC 59:
22 Sulbactam:ETX2514: A novel combination against MDR A. baumannii Sulbactam:ETX2514 * maintains excellent activity over time MIC distributions for globally diverse A. baumannii clinical strains MIC (mg/l) > N= N= N= N=1131 Cumul % susceptible Cumul % susceptible Cumul % susceptible Cumul % susceptible *held at 4 mg/l 22
23 % s u s c e p t i b l e s t r a i n s Sulbactam:ETX2514 activity remains unchanged in carbapenemresistant, colistin-resistant and MDR A. baumannii strains M I C ( m g / L ) s u l b a c t a m : E T X v s. M E M - R ( N = ) s u l b a c t a m a l o n e v s. a l l ( N = ) s u l b a c t a m : E T X v s. a l l ( N = ) s u l b a c t a m : E T X v s. C O L - R ( N = 5 6 ) s u l b a c t a m : E T X v s. M D R ( N = ) 23
24 Sulbactam:ETX2514 is active against A. baumannii encoding multiple β-lactamases Summary of MICs (mg/l) drug N range MIC 50 MIC 90 imipenem > SUL- ETX
25 Morphology of A. baumannii in the presence of sulbactam:etx2514 suggests multi-target effects No Drug ETX2514 SUL SUL-ETX2514 A. baumannii ATCC was exposed to 1/2X MIC of drug for 3 hrs at 35 C and examined by light microscopy. Scale bar = 5 mm. 25
26 Frequency of spontaneous resistance to sulbactam-etx2514 is very low against clinical isolates of A. baumannii Strain β-lactamase content FOR at 4X MIC Variant Protein affected SUL- ETX2514 MIC (mg/l) SUL MEM CAZ Parent -- 1/ ARC2058 ARC2681 ARC2782 ADC-99-like; OXA-95 ADC-42-like; TEM- 1; OXA-40; OXA- 132 ADC-79; TEM-1; PER-1; OXA-23; OXA-66 2X-1 AspS [Q47P] 16/ <9.0 x X-2 GltX [M240I] 16/ X-3 GltX [R117S] 64/ XL-1 PBP3 [V505L] 16/ x 10 Parent -- 2/ X-1 PBP3 [S390T] >64/4 > <9.0 x 10 Parent / >512 2X-1 PBP3 [T511A] 4/ >512 trna synthetase mutants are associated with the stringent response and are commonly seen with PBP2 inhibitors 1 Mutations in PBP3 affected the MIC of SUL-ETX2514 and sulbactam alone Resistant mutants suggest sulbactam-etx2514 works by inhibiting both PBP2 and PBP3 1 Vinella et al. (1992) EMBO J. 11:
27 Log(CFU/g) Log(CFU/g) Sulbactam:ETX2514 exhibits excellent in vivo activity Greater than 2-log kill achieved in both neutropenic mouse thigh and lung models of A. baumannii infections Sulbactam/ETX2514 dose response (SC, 4/1 ratio) MDR A. baumannii ARC3486 (OXA-72, OXA-66, TEM-1, AmpC) MIC(sulbactam) 32 mg/l, MIC(sulbactam/ETX2514) = 0.5 mg/l 10 Thigh 10 Lung Stasis Stasis Pretreatment Pretreatment Vehicle 2.5 / / / / 5 30 / / / 20 sulbactam/etx2514 (mg/kg) q3h 2 Vehicle 2.5 / / / / 5 30 / / / 20 sulbactam/etx2514 (mg/kg) q3h Similar results obtained for 5 additional clinical isolates 27
28 PK and safety of sulbactam:etx2514 Rat and dog PK of ETX2514 showed low to moderate clearance and low volume of distribution translating to a projected half life of 1.1 hr in humans Excretion of unchanged drug was the predominant clearance mechanism with relatively low metabolism characterized in vitro and in vivo ETX2514 was well-tolerated in both rat and dog 14-day repeat dose toxicology studies up to 2000 mg/kg with no significant clinical findings after intravenous administration no changes in ophthalmology, urinalyses, hematology parameters or organ weight In CV safety pharmacology studies, ETX2514 had no effects on qualitative electrocardiogram parameters, heart rates, or arterial pressures up to 2000 mg/kg 28
29 Summary and Conclusions ETX2514 is a potent inhibitor of a broad-spectrum of Class D β-lactamases while maintaining exquisite potency on Class A and C enzymes. ETX2514 potently restores the activity of multiple β-lactams in Gram-negative MDR pathogens. Sulbactam:ETX2514 is a novel BL:BLI combination to treat MDR A. baumannii infections, with an MIC 90 = 4 mg/l (N = 1742 clinical isolates) and excellent in vivo activity. Currently in Phase I testing 29
30 Acknowledgements AstraZeneca Antibacterial Discovery IHMA, Inc. Linneas 30
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationDiscovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β-lactamases, for the
Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β-lactamases, for the treatment of Gramnegative infections Thomas Durand-Réville 253 rd ACS National Meeting MEDI 332 April
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationBreakthrough medicines targeting the growing global health threat of antibiotic resistance. Jefferies Healthcare Conference June 2017
Breakthrough medicines targeting the growing global health threat of antibiotic resistance Jefferies Healthcare Conference June 2017 June 2017 Our Mission To build an enduring biopharmaceutical company
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationGlobal Alliance for Infections in Surgery. Better understanding of the mechanisms of antibiotic resistance
Better understanding of the mechanisms of antibiotic resistance Antibiotic prescribing practices in surgery Contents Mechanisms of antibiotic resistance 4 Antibiotic resistance in Enterobacteriaceae 9
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationThe impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationIntroduction to antimicrobial agents
Introduction to antimicrobial agents Kwan Soo Ko Action mechanisms of antimicrobials Bacteriostatic agents, such as tetracycline - Inhibit the growth and multiplication of bacteria - Upon exposure to a
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationUK guidelines for GNB infections
UK guidelines for GNB infections PROFESSOR PETER M. HAWKEY Institute of Microbiology and Infection (IMI), University of Birmingham, Birmingham, B14 2TT, UK Public Health England (PHE), Public Health Laboratory
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationBeta-lactamase Inhibitors May Induce Resistance to Beta-lactam Antibiotics in Bacteria Associated with Clinical Infections Bhoj Singh
Noto-are 14947537: Medicine. 2018-06-03. Beta-lactamase Inhibitors May Induce Resistance to Beta-lactam Antibiotics in Bacteria Associated with Clinical Infections Bhoj Singh Indian Veterinary Research
More informationß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems
β-lactams ß-lactams Sub-families Penicillins Cephalosporins Monobactams Carbapenems ß-lactams Mode of action PBPs = Trans/Carboxy/Endo- peptidases PBP binding (Penicillin-Binding Proteins) activation of
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More information1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS
PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...
More informationEXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS
EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS David J. Feola, Pharm.D., Ph.D. Assistant Professor University of Kentucky College of Pharmacy Disclosures Research Funding Pfizer Objectives
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationPrevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationchapter 15 microbial mechanisms of pathogenicity
chapter 15 microbial mechanisms of pathogenicity pathogenesis portals of entry & exit inoculation vs. disease: preferred portal of entry entry DOES NOT EQUAL disease entry into preferred portal of entry
More informationAntimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationβ-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018
β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus
More informationMicrobiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:
Microbiology Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention June 2017 MeshHp (VS) Medical Care Center Dr. Eberhard & Partner Dortmund (ÜBAG) www.labmed.de MVZ Dr. Eberhard &
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationPrevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31
More informationAntibiotics 201: Gramnegatives
Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More information10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide
I have no conflicts of interest in relation to this program Whitney Jones, PharmD Antimicrobial Stewardship Pharmacist Vanderbilt University Medical Center October 25, 2012 Understand the epidemiology
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationDr Kamini Walia Indian Council of Medical Research
Dr Kamini Walia Indian Council of Medical Research The apex body in India for the formulation, coordination and promotion of biomedical research under Department of Health Research, Ministry of Health
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationcrossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-negative pathogens between
RESEARCH ARTICLE Clinical Science and Epidemiology crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationon April 8, 2018 by guest
AAC Accepted Manuscript Posted Online 9 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02252-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 Antimicrobial
More informationPrevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae
Prevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae Dawn Terashita MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health September 28, 2017
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationHospital ID: 831. Bourguiba Hospital. Tertiary hospital
Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017
More informationAntibiotics 201 for Laboratory Professionals
Antibiotics 201 for Laboratory Professionals Erik Munson, Ph.D., D(ABMM) Marquette University Wisconsin Clinical Laboratory Network Technical Advisory Group The presenter states no conflict of interest
More informationOld bugs - new tricks Microbiology of UTIs in Dr Tim Collyns Consultant Microbiologist Leeds Teaching Hospitals NHS Trust
Old bugs - new tricks Microbiology of UTIs in 2010 Dr Tim Collyns Consultant Microbiologist Leeds Teaching Hospitals NHS Trust Microbiological aetiology of UTIs Collateral damage associated with antibiotics
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationAntibiotics 201 for Laboratory Professionals
Antibiotics 201 for Laboratory Professionals Erik Munson, Ph.D., D(ABMM) Marquette University Wisconsin Clinical Laboratory Network Technical Advisory Group The presenter states no conflict of interest
More informationNon-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
More informationThe discovery of antibiotics heralded
New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms Troy Kish, PharmD, BCPS The discovery of s heralded a new era of medicine; however, the curtain is beginning to draw on this
More informationPharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens
Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationAcinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.
Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More information